Osteoporosis and MRONJ in Dental Practice
On this page
Direct answer
Osteoporosis itself contraindicates nothing in dentistry — the drugs that treat it do: bisphosphonates and denosumab are linked to medication-related osteonecrosis of the jaw (MRONJ), defined as exposed bone in the maxillofacial region persisting more than eight weeks in a patient on a bone-modifying agent without radiotherapy. Risk is stratified by route: oral bisphosphonates for osteoporosis (alendronate 70 mg weekly) carry low risk — commonly quoted around 0.1 percent — while intravenous bisphosphonates and denosumab in oncology carry risks an order of magnitude higher, and dentoalveolar surgery, especially extraction, is the dominant trigger. The highest-value dental act is chronological: screen and stabilise the mouth before the first tablet — restore, treat periodontitis, extract doomed teeth and complete prosthetic adjustments — because a clean mouth entering therapy almost never necroses.
What you must remember
- MRONJ definition (quote all four limbs): exposed bone in the jaw, persisting more than eight weeks, in a patient current or previously on antiresorptive or antiangiogenic therapy, with no history of radiotherapy to the region.
- Risk gradient: oral bisphosphonate for osteoporosis roughly 0.01-0.1 percent; intravenous bisphosphonates (zoledronate) or denosumab in cancer — commonly quoted in single-digit percentages, several-fold to orders of magnitude higher.
- Risk multipliers: dentoalveolar surgery (extraction first), glucocorticoid co-therapy, diabetes, smoking, poor oral hygiene, chemotherapy, and longer duration of therapy (beyond about three to four years of oral bisphosphonate).
- Pre-therapy protocol: dental examination with radiographs before starting — eliminate infection sources, extract unrestorable teeth at least one to two weeks before therapy, complete prosthetic adjustment to remove trauma.
- Preventive maintenance on therapy: meticulous hygiene, regular recall, treat conservatively — retained roots can often be left rather than extracted in low-risk osteoporosis patients, per clinical judgement and physician liaison.
- Established MRONJ management: conservative — chlorhexidine rinses, antibiotics for infection, analgesia, superficial debridement; surgery reserved for refractory cases in specialist hands.
- Drug holiday caveat: pausing bisphosphonates before extraction has weak evidence and is the prescriber's decision, not the dentist's — the exam wants the referral, not the unilateral stop.
The extraction before the tablet
A 63-year-old postmenopausal woman reports her physician is starting alendronate next month for osteoporosis. Your move: this is the golden window. Full examination with radiographs now: a root-carious lower molar beyond restoration and a periodontally hopeless premolar come out now, while her jaw healing biology is drug-free; periodontal therapy is completed; the over-extended denture flange that has been ulcerating her vestibule is corrected, because chronic mucosal trauma is itself a necrosis trigger. She enters therapy with a stable mouth — her lifetime MRONJ risk from the oral drug is now close to the background rate. Fast-forward three years: a fractured root surfaces in that same quadrant. The decision tree has changed: in a low-risk oral-bisphosphonate patient of three years' duration, extraction remains acceptable — atraumatic technique, alveoloplasty to remove sharp edges, primary closure where possible, chlorhexidine, close follow-up to epithelialisation. Had she instead been a myeloma patient on monthly zoledronate, the calculus flips — attempt conservative management first, involve the oncologist, and if extraction is unavoidable, do it in a specialist setting with the team informed. Same tooth, opposite risk class, different plan.
Where students slip
The definition is where marks leak: candidates remember "exposed bone" and forget the eight-week persistence, the drug exposure, or the no-radiotherapy limb — all four belong together, and radiation osteonecrosis is the separate entity excluded by the last limb. The second slip is conflating risk classes — treating a weekly-alendronate osteoporosis patient like a monthly-zoledronate cancer patient, either by refusing needed extractions (over-treatment of the low-risk) or by casual surgery in the high-risk (catastrophe). Third: the pre-therapy screening question is a sequencing question — "the physician phones about starting bisphosphonates; what do you do?" — and the pass answer is complete dental stabilisation first, not "no special action". Fourth, know the modern umbrella term MRONJ replaced BRONJ when denosumab and antiangiogenics joined the list; using only "BRONJ" dates a candidate. Fifth, the management of established MRONJ is conservative-first — chlorhexidine, antibiotics when infected, analgesia — with surgical sequestrectomy reserved for refractory disease; aggressive early resection is the wrong-answer option in every MCQ.
Frequently asked questions
What is the definition of MRONJ?
Exposed jaw bone persisting more than eight weeks, in a patient taking or previously taking an antiresorptive or antiangiogenic agent, with no history of radiation therapy to the jaws.
How does risk differ between oral and intravenous bisphosphonates?
Oral therapy for osteoporosis carries roughly 0.01-0.1 percent risk; intravenous therapy in oncology (and denosumab at cancer doses) is an order of magnitude or more higher.
What dental care should precede bisphosphonate therapy?
Complete screening and stabilisation — restore, treat periodontitis, extract hopeless teeth and adjust prostheses — ideally at least a week or two before the first dose.
Can extractions be done on a patient taking alendronate?
Yes in most low-risk osteoporosis patients, atraumatically with chlorhexidine and close review; complex cases, longer therapy duration and cancer-dose therapy go to specialist coordination.
How is established MRONJ managed?
Conservatively — chlorhexidine rinses, systemic antibiotics for infection, analgesia and superficial debridement; surgical resection only for refractory cases in specialist hands.